Drug Target Review

MARCH 4, 2025

Knowing a patients subtype or phenotype can be used to guide obesity treatments of all kinds, including drug therapy, devices, bariatric surgery and even diet and lifestyle interventions, Bagnall explains.

Therapies 52

Therapies Treatment Clinical Trials Science 52

BioPharma Drive: Drug Pricing

JUNE 4, 2024

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

Therapies 182

Therapies Pharmaceuticals Trials Treatment 182

Drug Discovery Today

JULY 30, 2020

Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases

Therapies 100

Therapies Pharmaceuticals Disease 100

DrugBank

OCTOBER 4, 2024

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Patent Watch

DECEMBER 9, 2024

In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”

Drugs 97

Drugs Drug Development Pharmaceuticals Production 97

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

PPD

NOVEMBER 11, 2024

As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients. According to the United Nation’s 2024 World Population Prospects data, the global population of those 65 years old and over will grow from 0.8

Drug Development 97

Drug Development Clinical Trials Drugs Small Molecule 97

Drug Hunter

SEPTEMBER 17, 2023

This month features many of the big reveals from the ACS fall 2023 first disclosures including Nurix’s BTK degrader and RAPT’s CCR4 autoimmune therapy. selective inhibitor developed by Vertex Pharmaceuticals for acute pain in Phase III clinical trials. Several of the molecules making the August list are in Ph.

Clinical Trials 206

Clinical Trials Trials Therapies Pharmaceuticals 206

Drug Target Review

FEBRUARY 1, 2024

Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? Investors have historically taken a ‘guilty until proven innocent’ approach to investing in neuroscience therapies. We were able to license a molecule from a multi-national pharmaceutical company.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Discovery Today

JANUARY 13, 2020

Joint Venture to develop next generation cell and gene therapies incorporating Affimer proteins

Pharmaceuticals 100

Pharmaceuticals Therapies 100

Drug Channels

SEPTEMBER 8, 2023

Nasir discusses how hubs help patients initiate and adhere to drug therapies. Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners.

Pharmaceuticals 97

Pharmaceuticals Therapies Production Drugs 97

Drug Discovery Today

AUGUST 14, 2020

Avacta has appointed Neil Bell, a highly experienced pharmaceutical and biotech industry executive, to lead the ongoing transition to a clinical stage biotech developing innovative cancer therapies

Therapies 113

Therapies Pharmaceuticals 113

Fierce BioTech

MAY 29, 2024

New Solutions for Aseptic Filling for Gene Therapy In the development of gene therapies, it is more important than ever to stay on top of the latest containment and aseptic filling solutions.

Therapies 52

Therapies Pharmaceuticals 52

Fierce BioTech

MAY 2, 2024

West Pharmaceutical Services (West) and Cytiva have teamed up to offer innovative and versatile fill finish solutions to efficiently meet the unique demands of advanced pharmaceutical applications. In this webinar, you will learn about: The challenges and risks related to the packaging and filling of high-value drug products.

Therapies 52

Therapies Packaging Pharmaceuticals Production 52

New Drug Approvals

APRIL 2, 2025

1] [2] It was developed by Vertex Pharmaceuticals , [5] and was approved for medical use in the United States in January 2025. [2] The application received Breakthrough Therapy , Fast Track and Priority Review designations by the FDA. The FDA granted approval of Journavx to Vertex Pharmaceuticals Incorporated. under nitrogen.

FDA 62

FDA Therapies Trials Treatment 62

Drug Target Review

AUGUST 6, 2024

Liver Fibrosis : Targeted therapies using ADCs could help reduce liver fibrosis and prevent the progression to cirrhosis. Expedited programs like the FDA’s Breakthrough Therapy Designation and Fast Track can shorten development timelines and reduce risk. CDMOs are crucial.

Therapies 119

Therapies Pharmaceutical Companies Disease Treatment 119

Crown Bioscience

NOVEMBER 11, 2024

The use of biomarkers has transformed the pharmaceutical industry by allowing researchers to develop therapies that target specific pathways in diseases. These can be proteins, genes, or other molecules that signal an abnormal or normal process in the body.

Drug Development 52

Drug Development Drugs Therapies Pharmaceuticals 52

Drug Target Review

JULY 11, 2024

To date, there are less than 30 known surface proteins that form the basis of all approved cancer-targeted therapies of all modalities, including antibody-drug conjugates (ADCs), T-cell engagers, CAR T-cells and radiopharmaceuticals. These could be targets for antibody-drug conjugates (ADCs), bi-specific antibodies, or other therapies.

Therapies 56

Therapies RNA Pharma Companies Disease 56

DrugBank

MARCH 7, 2024

Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 98

DrugBank

AUGUST 20, 2024

If you're a pharmaceutical researcher or drug developer, understanding these breakthroughs is critical to staying at the forefront of innovation. You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy.

Therapies 98

Therapies Pharmaceuticals Disease Research 98

Alta Sciences

OCTOBER 21, 2024

BioPharma Dive: Pharmaceutical Research on mRNA and CAR T-Cell Therapy in Cancer — Pioneering the Future of Oncology aasimakopoulos Mon, 10/21/2024 - 13:18 Category News Tags Clinical Trials Preclinical Research Weight 1

Therapies 40

Therapies Pharmaceuticals Clinical Trials Research 40

DrugBank

JANUARY 22, 2025

Environmental Impacts of Traditional Pharmaceutical Production Traditional pharmaceutical manufacturing is complex, with each phase contributing to environmental degradation. The extraction and synthesis of active pharmaceutical ingredients (API) utilize vast amounts of water and energy.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Production Government 52

Chemical Biology and Drug Design

SEPTEMBER 13, 2023

This review aims to provide information on cutting-edge Nano particulate-based technologies and Nano therapies for colorectal cancer. The field of cancer detection and therapy has undergone a revolution with the development of nanotechnology for targeted drug delivery.

Drugs 100

Drugs Therapies Science Pharmaceuticals 100

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

DrugBank

DECEMBER 18, 2024

A new shift is occurring in the pharmaceutical industry, leading to a rapidly expanding field known as digital therapeutics (DTx). DTx interventions include sensor-equipped wearable devices, remote patient monitoring tools, and virtual reality platforms integrated with conventional pharmaceutical treatments.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Treatment Therapies 52

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies 52

Therapies Virus DNA Compliance 52

Chemical Biology and Drug Design

JUNE 19, 2024

Exploring the transformative impact of large language models (LLMs) in molecular biology and drug development, discussing potential areas of applications and breakthroughs in personalized therapies. While enhancing molecular biology aspects, we also address ethical concerns ensuring responsible application of these models.

Molecular Biology 100

Molecular Biology Drug Development Drugs Therapies 100

Antidote

JULY 29, 2022

billion to bring a new therapy to market. In 2019 alone, research and development spending totaled $186 billion for the global pharmaceutical industry. Between 2009 and 2018, U.S.

Clinical Trials 96

Clinical Trials Trials Therapies Pharmaceuticals 96

Drug Target Review

NOVEMBER 27, 2023

By directly interfering with the eIF4F complex, eFFECTOR’s STRIs provide a promising avenue for disrupting the core mechanisms of cancer, offering the potential to improve patient outcomes and overcome the limitations of traditional cancer therapies. Prior to Anadys Pharmaceuticals, Inc., Prior to Anadys Pharmaceuticals, Inc.,

Molecular Biology 86

Molecular Biology Therapies Pharmaceuticals Treatment 86

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Channels

MARCH 22, 2024

Adam discusses how patients seeking to access specialty therapies can benefit from a digital intake approach. He then explains three ways that specialty pharmaceutical companies can use digital intake strategies to speed patient enrollment. Today’s guest post comes from Adam Stotts, SVP of Customer Success at AssistRx.

Pharmaceutical Companies 98

Pharmaceutical Companies Therapies Pharmaceuticals Drugs 98

Drug Target Review

JANUARY 8, 2024

Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a commercial stage pharmaceutical company. acquired by Teva Pharmaceuticals in 2014.

Science 145

Science Disease FDA Approval Clinical Trials 145

DrugBank

JUNE 6, 2024

From Data to Therapy: Transforming Cancer Treatment One of the most exciting aspects of RADR ® is its potential to transform real-world outcomes for patients. The company plans to continue expanding the capabilities of RADR ® , with a significant focus on immuno-oncology, combination therapy prediction, and the development of ADCs.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

New Drug Approvals

APRIL 11, 2025

This article incorporates text from this source, which is in the public domain. ^ “Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors” Sanofi (Press release). 28 March 2025. Retrieved 29 March 2025. World Health Organization (2016). hdl : 10665/331046.

Clinical Trials 106

Clinical Trials FDA FDA Approval Trials 106

The Pharma Data

FEBRUARY 24, 2022

Designation is supported by Phase II efficacy and safety data that will be presented at ATS 2022 Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases. senior vice president, Medicine and Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “BI

Therapies 52

Therapies FDA Clinical Trials Disease 52

Drug Target Review

JUNE 27, 2023

We embark on a fascinating journey through the realms of cell and gene therapy, CRISPR technology, cancer research, and the latest advancements in screening and imaging. Prepare to be captivated by the groundbreaking discoveries and innovative approaches revolutionising the field of healthcare. But it doesn’t stop there.

Drugs 97

Drugs Therapies Engineering Disease 97